| Balance Sheets | 2025-09-30 | 2025-06-30 | ||
|---|---|---|---|---|
| Cash and cash equivalents | 112,724 | 96,648 | ||
| Marketable securities | 289,113 | 284,495 | ||
| Accounts receivable, net | 72,620 | 58,334 | ||
| Inventory | 3,836 | 3,873 | ||
| Other receivables | 1,716 | 1,906 | ||
| Prepaid expenses | 21,695 | 29,173 | ||
| Total current assets | 501,704 | 474,429 | ||
| Restricted cash, non-current | 2,563 | 2,563 | ||
| Inventory, non-current | 2,532 | 2,532 | ||
| Property and equipment, net | 5,746 | 3,182 | ||
| Intangible assets, net | 7,606 | 7,846 | ||
| Operating lease right-of-use assets | 10,233 | 229 | ||
| Long-term investments | 3,000 | 3,000 | ||
| Other assets | 1,177 | 1,213 | ||
| Total assets | 534,561 | 494,994 | ||
| Accounts payable and other accrued liabilities | 103,498 | 78,641 | ||
| Accrued payroll and benefits | 13,552 | 11,612 | ||
| Total current liabilities | 117,050 | 90,253 | ||
| Long-term debt, net | 72,281 | 72,129 | ||
| Other long-term liabilities | 10,148 | - | ||
| Total liabilities | 199,479 | 162,382 | ||
| Common stock, 0.0001 par value 200,000,000 shares authorized 42,447,882 shares issued and outstanding at september30, 2025 (unaudited) 38,349,826 shares issued and outstanding at december31, 2024 | 6 | 6 | ||
| Additional paid-in capital | 753,042 | 738,237 | ||
| Accumulated other comprehensive income (loss) | 289 | 39 | ||
| Accumulated deficit | -418,255 | -405,670 | ||
| Total stockholders equity | 335,082 | 332,612 | ||
| Total liabilities and stockholders equity | 534,561 | 494,994 | ||
Tarsus Pharmaceuticals, Inc. (TARS)
Tarsus Pharmaceuticals, Inc. (TARS)